Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( (HK:1558) ).
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced the fulfillment of all pre-conditions for its proposed conditional privatization through a merger by absorption with Sunshine Lake Pharma Co., Ltd. This development marks a significant step forward in the merger process, with the Stock Exchange approving the listing of the Offeror H Shares, which are to be issued as consideration for the cancellation of the Share Exchange H Shares under the merger. The completion of these pre-conditions indicates progress in the merger, potentially impacting the company’s market positioning and stakeholder interests.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
More about YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development, production, and sale of pharmaceutical products. The company is based in the People’s Republic of China and is involved in a merger with Sunshine Lake Pharma Co., Ltd.
Average Trading Volume: 9,624,738
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.35B
For an in-depth examination of 1558 stock, go to TipRanks’ Overview page.